Frédéric Hammel

Frédéric Hammel is a venture partner at Elaia Partners and represents the firm on Nosopharm’s supervisory board. He is the managing director of Ethera, a spin-off from CEA (the French Alternative Energies and Atomic Energy Commission) / CNRS (the French National Center for Scientific Research) developing high-performance air quality solutions.

Frédéric has over 25 years’ experience gained in industrial companies and subsequently in technology startups. Prior to joining Ethera, Frédéric led projects in the life sciences sector, spanning therapeutic development, medical devices and diagnostics.

He is a former student of the Ecole Normale Supérieure in Paris, France, where he obtained a master’s in biology and a postgraduate diploma in pharmacology. He also has an MBA from the Collège des Ingénieurs (France).

In joining Nosopharm, he brings with him his expertise in the pharmaceutical industry and biotechnology business management. Frédéric has particular experience in fundraising from venture capital companies.